BTIG Reiterates Buy on Denali Therapeutics, Maintains $39 Price Target

Benzinga · 1d ago
BTIG analyst Thomas Shrader reiterates Denali Therapeutics (NASDAQ:DNLI) with a Buy and maintains $39 price target.